Abstract
Clazosentan, an endothelin ETA antagonist, is under development by Actelion (formerly Axovan), under license from F Hoffman-La Roche, for the potential prevention of cerebral infarction and ischemia induced by cerebral vasospasm following subarachnoid hemorrhage. Results from the phase IIb portion of a phase IIb/III clinical study are expected in the first half of 2006.
MeSH terms
-
Clinical Trials, Phase III as Topic
-
Dioxanes / antagonists & inhibitors
-
Dioxanes / therapeutic use
-
Endothelin-1 / antagonists & inhibitors*
-
Humans
-
Molecular Conformation
-
Pyridines / antagonists & inhibitors
-
Pyridines / therapeutic use
-
Pyrimidines / antagonists & inhibitors
-
Pyrimidines / therapeutic use
-
Subarachnoid Hemorrhage / drug therapy*
-
Sulfonamides / antagonists & inhibitors
-
Sulfonamides / therapeutic use
-
Tetrazoles / antagonists & inhibitors
-
Tetrazoles / therapeutic use
-
Vasoconstriction / drug effects*
-
Vasoconstrictor Agents / chemistry
-
Vasoconstrictor Agents / therapeutic use*
-
Vasospasm, Intracranial / drug therapy*
Substances
-
Dioxanes
-
Endothelin-1
-
Pyridines
-
Pyrimidines
-
Sulfonamides
-
Tetrazoles
-
Vasoconstrictor Agents
-
clazosentan